ScholarIQanswers from OpenAlex & ORCID
Peter Sleight
ResearcherPublications, citations & collaboration network
Peter Sleight is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Peter Sleight have?
ScholarIQindexed works
Peter Sleight has 614 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Peter Sleight have?
ScholarIQcitation count
Peter Sleight has 71,694 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Peter Sleight?
ScholarIQh-index
Peter Sleight has an h-index of 103 in OpenAlex.
What is the i10-index of Peter Sleight?
ScholarIQi10-index
Peter Sleight has an i10-index of 315 in OpenAlex.
What is the OpenAlex record for Peter Sleight?
ScholarIQopenalex
The OpenAlex for Peter Sleight is on the source record.
What are the most-cited papers on Peter Sleight?
ScholarIQmost cited works
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz, Josep Redón, Alberto Zanchetti, Michael Böhm, Thierry Christiaens, Renata Cífková, Guy De Backer, Anna F. Dominiczak, Maurizio Galderisi, Diederick E. Grobbee, Tiny Jaarsma, Paulus Kirchhof, Sverre E. Kjeldsen, Stéphane Laurent, Athanasios Manolis, Peter M. Nilsson, Luís M. Ruilope, Roland E. Schmieder, Per Anton Sirnes, Peter Sleight, Margus Viigimaa, Bernard Waeber, Faı̈ez Zannad
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent, Martin Landray, Christina Reith, Jonathan Emberson, David C. Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan C. Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Y. Agodoa, Mike Gaziano, Bertram L. Kasiske, Robert Walker, Ziad A. Massy, Bo Feldt‐Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimı́r Tesař, Andrzej Więcek, Diederick E. Grobbee, Dick de Zeeuw, Carola Grönhagen‐Riska, Tanaji Dasgupta, David Lewis, William G. Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard H. Grimm, Terje Pedersen, Jonathan A. Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
HPS2-THRIVE Collaborative Group, R. Haynes, Lixin Jiang, Jemma C. Hopewell, Jing Li, F Chen, S. Parish, Martin Landray, R. Collins, J. Armitage, R. Collins, J. Armitage, C. Baigent, Z. Chen, Martin Landray, Yang Chen, Lixin Jiang, Terje Pedersen, Martin Landray, Louise Bowman, F Chen, Michael Hill, R. Haynes, Carol Knott, Kazem Rahimi, Jonathan A. Tobert, Peter Sleight, David Simpson, S. Parish, Alex Baxter, M. Lay, Christopher Bray, E. Wincott, G. van Leijenhorst, A. Skattebøl, Gro Kvelprud Moen, Yale Mitchel, O. Kuznetsova, Stephen MacMahon, John Kjekshus, Catherine J. Hill, TH Lam, Peter Sandercock, Richard Peto, Jemma C. Hopewell